Scope
This focused ASRA educational case discussion describes selected recommendations attributed to the fifth-edition guidance on regional or neuraxial anaesthesia in patients receiving antithrombotic therapy. It is not the complete guideline or a complete interruption, catheter-removal and restart schedule.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Assessment and reversal
- For elective neuraxial procedures, the discussion states that warfarin is held for five days. For urgent reversal, vitamin K, prothrombin complex concentrate or fresh frozen plasma may be considered. [1]
- When anti-Xa testing is used to assess a direct oral anticoagulant, the assay must be calibrated to that specific medication. [1]
- Routine use of reversal agents to enable neuraxial procedures is not recommended in routine patients; the discussion includes andexanet alfa, idarucizumab and PCC among these agents. [1]
- PT, INR and aPTT have poor reliability for evaluating dabigatran in this setting. [1]
Dose-dependent interruption
- The discussion describes a 72 hours hold for its high-dose apixaban, rivaroxaban and edoxaban examples. Its high-dose apixaban examples include 5mg BID or greater and 2.5mg twice a day in people <60kg or with significantly reduced kidney function; a reduced tablet dose should therefore not automatically be treated as low-dose therapy. [1]
- For the low-dose regimens described, apixaban is 2.5mg twice a day and rivaroxaban is 10mg once a day with CrCl >15mL/min. The stated intervals are 36 hours after the last low-dose apixaban and 24 hours after the last low-dose rivaroxaban; rivaroxaban uses 30 hours when CrCl is 15–30mL/min. [1]
- No low-dose edoxaban guidance is supplied by the recommendations discussed here. [1]
Heparin
- Stopping subcutaneous or intravenous heparin requires both a hold period and confirmation of normal coagulation. In the intravenous-heparin epidural case, the discussion specifies a 4–6 hours hold and a blood test showing normal coagulation, such as aPTT. [1]
Limitations and use
- Selected statements from a society educational case discussion are summarized, not the full guideline.
- Residual drug-concentration thresholds are not included, and the extract does not establish a complete approach to neuraxial catheter removal or postoperative restart.
- The low- and high-dose categories, renal function and patient characteristics must be read together; this summary does not supply every drug-specific schedule.
- A stated interruption interval alone does not establish procedural clearance. This selected discussion does not supply all required preprocedure coagulation criteria, including for warfarin.
- This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Regional anaesthesia with antithrombotic or thrombolytic therapy: fifth edition — focused recommendation source
Selected recommendation material consulted
Publication details
- Issuing organisation
- ASRA Pain Medicine
- First published
- 29 January 2025
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.